Squamous cell carcinoma of penis
diseaseOn this page
Also known as epidermoid carcinoma of penisepidermoid carcinoma of the penisepidermoid cell carcinoma of penisepidermoid cell carcinoma of the penispenile epidermoid carcinomapenile epidermoid cell carcinomapenile squamous car.(epidermoid)penile squamous carcinoma (epidermoid)penile squamous cell cancerpenile squamous cell carcinomapenis squamous cell carcinomaPSCCsquamous cell carcinoma of the penis
Summary
Squamous cell carcinoma of penis (MONDO:0018352) is a cancer (an umbrella term covering 5 Mondo subtypes) and 19 clinical trials. Top therapeutic interventions include afatinib, enfortumab vedotin, and cabozantinib. A subtype of squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 19
Clinical features
Epidemiology
Prevalence records
24 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.57 | Europe | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.612 | Netherlands | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.491 | Austria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.605 | Belgium | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.516 | Bulgaria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.423 | Croatia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.684 | Czech Republic | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.6 | Estonia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.426 | Finland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.638 | Germany | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.682 | Iceland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.475 | Ireland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.606 | Italy | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.552 | Latvia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.517 | Lithuania | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.628 | Malta | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.744 | Norway | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.396 | Poland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.745 | Portugal | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.499 | Slovakia | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | squamous cell carcinoma of penis |
| Mondo ID | MONDO:0018352 |
| Orphanet | 398058 |
| DOID | DOID:5518 |
| ICD-11 | 186592209 |
| NCIT | C7729 |
| SNOMED CT | 403468003 |
| UMLS | C0238348 |
| MedGen | 116057 |
| GARD | 0021639 |
| Anatomy (UBERON) | UBERON:0000989 |
| Is cancer (heuristic) | yes |
Also known as: epidermoid carcinoma of penis · epidermoid carcinoma of the penis · epidermoid cell carcinoma of penis · epidermoid cell carcinoma of the penis · penile epidermoid carcinoma · penile epidermoid cell carcinoma · penile squamous car.(epidermoid) · penile squamous carcinoma (epidermoid) · penile squamous cell cancer · penile squamous cell carcinoma · penis squamous cell carcinoma · PSCC · squamous cell carcinoma of penis · squamous cell carcinoma of the penis
Data availability: 12 cell lines.
Disease family
This is a subtype of squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › squamous cell carcinoma of penis
Related subtypes (38): bone squamous cell carcinoma, prostate squamous cell carcinoma, trachea squamous cell carcinoma, scrotum squamous cell carcinoma, skin squamous cell carcinoma, bladder squamous cell carcinoma, urethra squamous cell carcinoma, papillary squamous carcinoma, basaloid squamous cell carcinoma, pseudoglandular squamous cell carcinoma, thymus squamous cell carcinoma, ovarian squamous cell carcinoma, renal pelvis squamous cell carcinoma, ureter squamous cell carcinoma, fallopian tube squamous cell carcinoma, squamous carcinoma in situ, keratinizing squamous cell carcinoma, squamous cell lung carcinoma, esophageal squamous cell carcinoma, squamous cell breast carcinoma, adenosquamous carcinoma, cervical squamous cell carcinoma, colorectal squamous cell carcinoma, endometrial squamous cell carcinoma, gallbladder squamous cell carcinoma, gastric squamous cell carcinoma, thyroid gland squamous cell carcinoma, vaginal squamous cell carcinoma, head and neck squamous cell carcinoma, squamous cell carcinoma of the corpus uteri, squamous cell carcinoma of the small intestine, squamous cell carcinoma of pancreas, squamous cell carcinoma of liver and intrahepatic biliary tract, human papillomavirus-related squamous cell carcinoma, sarcomatoid squamous cell carcinoma, vulvar squamous cell carcinoma, metastatic squamous cell carcinoma, pure squamous carcinoma of the urothelial tract
Subtypes (5): sarcomatoid penile squamous cell carcinoma, penis mixed squamous cell carcinoma, papillary carcinoma of the penis, penis carcinoma in situ, human papillomavirus-related penile squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 19.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| PHASE1 | 3 |
| Not specified | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT06104618 | PHASE2 | RECRUITING | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis |
| NCT06161532 | PHASE2 | RECRUITING | Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C… |
| NCT06353906 | PHASE2 | RECRUITING | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer |
| NCT07110038 | PHASE2 | RECRUITING | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma |
| NCT01807546 | PHASE2 | COMPLETED | Oral Rigosertib for Squamous Cell Carcinoma |
| NCT02014831 | PHASE2 | WITHDRAWN | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) |
| NCT02279576 | PHASE2 | TERMINATED | Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) |
| NCT02541903 | PHASE2 | TERMINATED | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma |
| NCT02837042 | PHASE2 | TERMINATED | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma |
| NCT03221400 | PHASE1/PHASE2 | UNKNOWN | PEN-866 in Patients With Advanced Solid Malignancies |
| NCT03774901 | PHASE2 | UNKNOWN | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma |
| NCT03943602 | PHASE2 | UNKNOWN | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT07217171 | PHASE1 | RECRUITING | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas |
| NCT03517488 | PHASE1 | COMPLETED | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
| NCT02104063 | Not specified | COMPLETED | Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] |
| NCT04996849 | Not specified | TERMINATED | Contemporary Characteristics of Penile Cancer |
| NCT06068998 | Not specified | COMPLETED | Molecular Characterization of Penile Cancers in Developing Countries |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| AFATINIB | 4 | 2 |
| ENFORTUMAB VEDOTIN | 4 | 2 |
| CABOZANTINIB | 4 | 1 |
| CETUXIMAB | 4 | 1 |
| NIRAPARIB | 4 | 1 |
| SACITUZUMAB GOVITECAN | 4 | 1 |
| RIGOSERTIB | 3 | 2 |
| VUDALIMAB | 2 | 1 |
| PEN-866 | 1 | 1 |
| CHEMBL3752204 | 0 | 1 |
| CHEMBL4215501 | 0 | 1 |
| CHEMBL4849721 | 0 | 1 |
| EXELIXIS | 0 | 1 |
| FOLINIC ACID | 0 | 1 |